Compare · CAI vs CI
CAI vs CI
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.61B, about 78.8x CAI ($971.9M).
- Over the past year, CAI is down 42.2% and CI is down 7.0% - CI leads by 35.2 points.
- CAI has been more active in the news (11 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 15 for CAI).
- Company
- Caris Life Sciences Inc.
- The Cigna Group
- Price
- $16.15-2.18%
- $289.50+0.00%
- Market cap
- $971.9M
- $76.61B
- 1M return
- -18.68%
- +1.94%
- 1Y return
- -42.16%
- -7.00%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 11
- 4
- Recent ratings
- 15
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CAI
- Caris Life Sciences Announces Share Repurchase Program
- Caris Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Poste George was granted 1,600 shares, increasing direct ownership by 10% to 17,729 units (SEC Form 4)
- Director Knowles Jonathan Kenneth Charles was granted 1,600 shares, increasing direct ownership by 0.52% to 308,979 units (SEC Form 4)
- Wolfe Research resumed coverage on Caris Life Sciences
- Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
- Officer Denton John Russel covered exercise/tax liability with 6,047 shares, decreasing direct ownership by 3% to 181,515 units (SEC Form 4)
- Officer Power Luke Thomas covered exercise/tax liability with 9,771 shares, decreasing direct ownership by 6% to 153,771 units (SEC Form 4)
- Officer Brille Brian J covered exercise/tax liability with 13,987 shares, decreasing direct ownership by 6% to 230,303 units (SEC Form 4)
- President Spetzler David Baxley covered exercise/tax liability with 13,856 shares, decreasing direct ownership by 3% to 530,083 units (SEC Form 4)
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group